EUVIMEDEUVIMED entdecken
Crossref

Deep-Learning Pharmacokinetic Modelling for Personalised Low-Dose Gadolinium in Oncological 3-Tesla MRI: A Diagnostic-Accuracy Study

Oliva Azalia Putri, Sony Sanjaya

Sriwijaya Journal of Radiology and Imaging Research · 13.07.2026 · 3 (2) · 83-91

DOI: 10.59345/sjrir.v3i2.290 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sriwijaya Journal of Radiology and Imaging Research, online erschienen am 13.07.2026. Verfasst von Oliva Azalia Putri und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Weight-based dosing of gadolinium-based contrast agents (GBCA; 0.1 mmol/kg) in oncological MRI disregards individual haemodynamics and tumour microvascularity, contributing to avoidable cumulative exposure and tissue-retention risk. We evaluated an artificial-intelligence (AI)-assisted pharmacokinetic-modelling approach to personalise and reduce GBCA dose while preserving diagnostic performance.

Methods

In this prospective, paired diagnostic-accuracy study reported per STARD 2015 at a tertiary hospital in Palembang, Indonesia, 152 adults (198 lesions) with histologically confirmed solid primary malignancies underwent 3.0-T contrast-enhanced MRI. A convolutional-neural-network extended-Tofts model derived each patient’s minimum effective gadobutrol dose, compared against the standard 0.1 mmol/kg protocol. Two radiologists, blinded to clinical data and to a composite reference standard (histopathology and ≥6-month imaging follow-up), assessed signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), 5-point diagnostic confidence and lesion characterisation. Sensitivity, specificity, AUC (DeLong), likelihood ratios, Cohen’s κ and McNemar testing were computed with 95% confidence intervals.

Results

The AI protocol reduced GBCA dose by 38.4% (4.6 vs 7.5 mL; p0.05). Inter-reader agreement was substantial-to-almost-perfect (characterisation κ 0.83; confidence κ 0.88). Diagnostic adequacy was maintained in 149/152 cases (98%).

Conclusions

AI-assisted pharmacokinetic modelling enabled a 38% gadolinium-dose reduction without loss of diagnostic accuracy or image quality, supporting personalised contrast administration and lower cumulative exposure in oncological MRI.

Zitieren

APA

Putri, O. A., & Sanjaya, S. (2026). Deep-Learning Pharmacokinetic Modelling for Personalised Low-Dose Gadolinium in Oncological 3-Tesla MRI: A Diagnostic-Accuracy Study. Sriwijaya Journal of Radiology and Imaging Research, 3(2), 83-91. https://doi.org/10.59345/sjrir.v3i2.290

Vancouver

Putri OA, Sanjaya S. Deep-Learning Pharmacokinetic Modelling for Personalised Low-Dose Gadolinium in Oncological 3-Tesla MRI: A Diagnostic-Accuracy Study. Sriwijaya Journal of Radiology and Imaging Research. 2026;3(2):83-91. doi:10.59345/sjrir.v3i2.290

BibTeX
@article{Putri2026,
  author = {Putri, Oliva Azalia and Sanjaya, Sony},
  title = {Deep-Learning Pharmacokinetic Modelling for Personalised Low-Dose Gadolinium in Oncological 3-Tesla MRI: A Diagnostic-Accuracy Study},
  journal = {Sriwijaya Journal of Radiology and Imaging Research},
  year = {2026},
  volume = {3},
  number = {2},
  pages = {83--91},
  doi = {10.59345/sjrir.v3i2.290}
}
Kostenlos starten →